ASX ANNOUNCEMENT **27 November 2013**

GENERAL PRE-REINSTATEMENT DISCLOSURE

The Board of Cynata Therapeutics Limited (ASX: CYP) is pleased to confirm the following:

(a) The License Agreement with Wisconsin Alumni Research Foundation effective on 26 March 2013 remains in full force and effect;

(b) Satisfaction of the conditions precedent and completion of the 11 Option Agreements between the Company and the vendors of Cynata Incorporated dated 12 July 2013 (**Option Agreements**) and the issue of 10,000,001 fully paid ordinary shares in the Company (on a post-consolidation basis) to the vendors of Cynata Incorporated in accordance with the Option Agreements;

(c) That there have been no material subsequent events to alter the Company's statement of financial position on page 48 of the Prospectus; and

(d) The Company is in compliance with the Listing Rules and in particular Listing Rule 3.1.

Dr Ross Macdonald
Managing Director & Chief Executive Officer
+61 412 119 343

About Cynata Therapeutics Limited
Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.